Juan Macías
0000-0002-4778-790X
202 papers found
Refreshing results…
Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment
Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients
Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients
Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients:
Liver Toxicity of Antiretroviral Combinations Including Fosamprenavir Plus Ritonavir 1400/100 mg Once Daily in HIV/Hepatitis C Virus-Coinfected Patients
Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C
Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype
Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients
Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV
Prediction of Response to Pegylated Interferon plus Ribavirin byIL28BGene Variation in Patients Coinfected with HIV and Hepatitis C Virus
Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin
Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry:
Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients
Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice
Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: Role of didanosine
Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients
HAART and the liver: Friend or foe?
HAART and the liver: friend or foe?
Efficacy and Safety of Pegylated Interferon plus Ribavirin in HIV and Hepatitis C Virus-Coinfected Patients with Advanced Immunosuppression
Liver Stiffness as a Predictor of Esophageal Varices Requiring Therapy in HIV/Hepatitis C Virus-Coinfected Patients With Cirrhosis:
Missing publications? Search for publications with a matching author name.